Bagel, Jerry, April Armstrong, Richard Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, and Christopher Griffiths. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy by Prior Treatment in the Phase 3 POETYK PSO-1 Trial”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s47. Accessed July 3, 2024. https://jofskin.org/33014/index.php/skin/article/view/1802.